J&J Sells DePuy Synthes Unit to Apollo for $20 Billion

Johnson & Johnson has been streamlining its operations to focus on high-growth areas of healthcare. The company's decision to sell DePuy Synthes, its orthopedics unit, for $20 billion is in line with this goal.

This move follows the spin-off of Kenvue, a consumer health business, in 2023. J&J has been shifting its focus from diversified conglomerates to more specialized healthcare operations.

The company's decision to sell DePuy Synthes is seen as a positive step towards increasing profitability and growth. The sale will provide J&J with cash for stock buybacks, debt reduction, or reinvestment in its business.